D-0561-2023 Class II Terminated

Recalled by PD-Rx Pharmaceuticals, Inc. — Oklahoma City, OK

FDA drug recall D-0561-2023 was initiated by PD-Rx Pharmaceuticals, Inc. on Apr 6, 2023 and is designated Class II. Reason for recall: CGMP deviations. The recall status is terminated (terminated Apr 30, 2024). Affected quantity: 393 bottles.

Recall details

Product Type
Drugs
Report Date
May 10, 2023
Initiation Date
Apr 6, 2023
Termination Date
Apr 30, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
393 bottles

Product description

Simvastatin USP 40 mg, Rx only, Intas Pharm. Limited Ahmedabad 380 054 India Pkg By: PD-Rx Pharmaceuticals Incorporated Oklahoma City, OK 73127 a) 30 count-bottle (NDC 43063-0726-30) b) 90 count-bottle (NDC 43063-0726-90)

Reason for recall

CGMP deviations.

Distribution pattern

Nationwide in the US.

Code information

Lots: a) A22A17, D22C21 Exp. 07/31/23; K22D89, L22B26, L22D14 Exp. 03/31/24; L22D96 Exp. 04/30/24; b) L21E06 Exp. 05/31/23; B22C05, D22B91, E22C82 Exp. 07/31/23; G22B03 G22B79, H22A30, J22B81 Exp. 08/31/23; J22F27, K22B37, K22B88 Exp. 10/31/23; L22D32 Exp. 03/31/24; B23E07 Exp. 04/30/24

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0561-2023
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0561-2023. Report a data issue: hello@regdatalab.com.